Alan Montgomery
Alan is Co-Head of our pharmaceuticals sector team and is Chair of our India practice.
Alan specialises in private and public cross-border mergers and acquisitions, restructurings, joint ventures and partnership matters, acting for international corporates and private capital clients. Alan is ranked as a leading M&A lawyer in the London market, is recognised as a leading lawyer for pharmaceuticals M&A and one of the top 10 international lawyers for India-related M&A work.
Experience & capabilities
Selected matters
- Dr Reddy's Laboratories on its £500m acquisition of Haleon’s global Nicotine Replacement Therapy business (ex-US)
- DawsonGroup on its sale to KKR
- Bharti Group and His Majesty's Government on the acquisition of OneWeb
- OneWeb on approx. $2 billion fundraisings and on its approx. US$7 billion merger with Eutelsat
- Genus plc on its US$160m joint venture with BCA
- Bharti Airtel on its US$10.7 billion acquisition of Zain Africa
- Lupin on its acquisitions of VISUfarma and Renascience and on its US$600 million auction sale of Kyowa Pharmaceutical to Unison
- Bharti Airtel on US$550 million of equity investments from TPG’s the Rise Fund, Qatar Holding, Chimera Investment and Mastercard into Airtel Africa’s mobile money platform, Airtel Money
- Ennismore, a UK-based developer and the owner of The Hoxton and Gleneagles, on its joint venture with Accor to create a new global lifestyle hotels company
- Zydus on its acquisition of Liqmeds
- Sterling Pharma Solutions on its disposal to GHO
- Strides Pharma Science on the disposal of its Australian business to its minority partner, Arrow Pharma and on the auction sale of its injectables business to Mylan for approx. US$1.6 billion
- Claris Lifesciences on the auction sale of its injectables business to Baxter for US$650 million
- SK Holdings on its acquisition of Yposkesi (a leading French gene therapy CDMO)
- Acacia Research Corporation on a its acquisition of interests in 19 public and private life sciences companies (including Oxford Nanopore, Immunocore, 4D Pharma and Kymab) from the LF Equity Income Fund for £223.9 million
- Aurobindo Pharma on its acquisition of the commercial operations of Apotex in five European countries, on its acquisition of a portfolio of European products from Mylan NV, in connection with the combination of Mylan and the Upjohn business of Pfizer and its acquisition of the commercial operations of Actavis in seven European countries
- Cipla on various significant pharmaceutical joint ventures in Africa and the Middle East
- Abbott on a variety of matters
- United Breweries on the £1.28 billion investment by Diageo in United
- Ernst & Young as administrators of Nortel's EMEA entities in connection with the disposals of Nortel's global Enterprise Solutions and GSM/GSMR businesses for over US$1 billion
- Central SAFE Investments on the sale of a 10% strategic interest in the Bank of China to a group of investors led by Royal Bank of Scotland for approximately US$3.1 billion
- Bharti Airtel on the disposal of its telecoms operations in Burkina Faso and Sierra Leone to Orange
- Pala Investments Limited on its public takeover of Sierra Rutile Limited
- Biffa on the contested £1.23 billion takeover offer from a consortium led by Montagu Private Equity and Global Infrastructure Partners
- HP Bulmer plc on its takeover by Scottish & Newcastle; Standard Chartered on its £440 million takeover of Axon Group plc
- Morgan Stanley on Severstal’s unsolicited offer for Celtic Resources Holdings plc
- Severn Trent plc on its demerger and subsequent listing of Biffa
- BP plc on the sale of its 2% stake in Sinopec on public markets for US$742 million and on the sale of its 2% stake in PetroChina Company on public markets for US$1.65 billion
Background
Alan is ranked as leading lawyer for transactional life sciences work in the Legal 500 and Chambers, and as one of the top 10 international lawyers for India-related M&A work.
Accolades
In life sciences and healthcare, Alan Montgomery is a standout attorney.
Legal 500: Healthcare and Life Sciences, 2026
Alan is my go-to for life sciences M&A. He is incredibly knowledgeable, has great commercial understanding and is very good at deal negotiations.
Chambers: Life Sciences, 2026
"Alan's legal acumen, clarity in structuring deals and responsiveness are exceptional. His ability to simplify complex legal positions also stands out."
Chambers UK 2026, Life Sciences
Alan Montgomery is lauded as "amongst the most dependable quality legal professionals, with the ability to analyse a matter in all its perspectives, quickly."
Chambers Asia Pacific 2016
Alan is "very committed, hard-working and quick in response, immaterial of the time of day."
Chambers Global 2016
Related insights
